Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2018

View Archived Issues

Study triples number of known blood pressure genes

Adult BACE1 knockouts have hippocampal issues

A new view on protein activity

IL-34 protects mice from lethal sepsis

Researchers develop a SLC6A8 deficiency rat model

MicroRNA-135a levels predict breast cancer outcome and response to tamoxifen treatment

EZH2 as a novel biomarker in pulmonary arterial hypertension

DS-21412020 demonstrates potent activity against respiratory pathogens

Polymorphisms in donor CYP3A5 and ABCB1 do not impact clinical outcome after kidney transplantation

HspB5 as a novel therapeutic target in cystic fibrosis

Cerevance initiates first-in-human study of CVN-424 for the treatment of Parkinson's disease

Revolution Medicines initiates phase I study of RMC-4630 in solid tumors

Ribomic evaluating RBM-007 in phase I/II study in exudative age-related macular degeneration

Antigen-expressing Listeria shows anticancer efficacy by remodeling the tumor microenvironment

Medshine Discovery divulges S1P1 receptor agonists

Patient enrollment ongoing in phase II study of M-1095 in chronic plaque-type psoriasis

Kangpu Biopharmaceuticals discloses PDE4 and TNF inhibitors

Beijing Scitech-Mq Pharmaceuticals presents tyrosine kinase inhibitors

Wockhardt identifies new compounds as antibacterials

Achillion Pharmaceuticals divulges complement factor D inhibitors

Santen and PeptiDream enter ophthalmic multitarget discovery and development agreement

DSMB clears continuation of phase I/IIa study of VBI-1902 in recurrent GBM

IntelGenx initiates phase IIa study of montelukast buccal film for Alzheimer's

European Commission approves pegfilgrastim biosimilar Udenyca

Targeting hepatic OGA ameliorates hyperammonemia researchers find

Japanese approval for Oravi for oropharyngeal candidiasis

JCR's agalsidase beta biosimilar approved in Japan for Fabry disease

CHK1 inhibition improves established PAH in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...